Media headlines about Adaptimmune Therapeutics (NASDAQ:ADAP) have trended positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of 0.32 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.0462661018498 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Adaptimmune Therapeutics (ADAP) opened at $8.22 on Wednesday. The stock has a market cap of $807.58, a price-to-earnings ratio of -10.82 and a beta of 1.74. Adaptimmune Therapeutics has a fifty-two week low of $3.88 and a fifty-two week high of $9.70.
A number of equities research analysts recently commented on ADAP shares. SunTrust Banks reissued a “buy” rating and set a $10.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, November 10th. ValuEngine cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. TheStreet raised shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd. Finally, BidaskClub cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.58.
COPYRIGHT VIOLATION NOTICE: “Favorable Press Coverage Somewhat Unlikely to Impact Adaptimmune Therapeutics (ADAP) Stock Price” was originally reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thestockobserver.com/2018/02/21/favorable-press-coverage-somewhat-unlikely-to-impact-adaptimmune-therapeutics-adap-stock-price.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.